Month: April 2022

Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II). The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Impact of homologous recombination status and responses with veliparib combined with first-line chemotherapy in ovarian cancer in the Phase 3 VELIA/GOG-3005 study.. Author is Swisher, Elizabeth M; Aghajanian, Carol; O’Malley, David M; Fleming, Gini F; Kaufmann, Scott H; Levine, Douglas A; Birrer, Michael J; Moore, Kathleen N; Spirtos, Nick M; Shahin, Mark S; Reid, Thomas J; Friedlander, Michael; Steffensen, Karina Dahl; Okamoto, Aikou; Sehgal, Vasudha; Ansell, Peter J; Dinh, Minh H; Bookman, Michael A; Coleman, Robert L.

OBJECTIVE: In the Phase 3 VELIA trial (NCT02470585), PARP inhibitor (PARPi) veliparib was combined with first-line chemotherapy and continued as maintenance for patients with ovarian carcinoma enrolled regardless of chemotherapy response or biomarker status. Here, we report exploratory analyses of the impact of homologous recombination deficient (HRD) or proficient (HRP) status on progression-free survival (PFS) and objective response rates during chemotherapy. METHODS: Women with Stage III-IV ovarian carcinoma were randomized to veliparib-throughout, veliparib-combination-only, or placebo. Stratification factors included timing of surgery and germline BRCA mutation status. HRD status was dichotomized at genomic instability score 33. During combination therapy, CA-125 levels were measured at baseline and each cycle; radiographic responses were assessed every 9 weeks. RESULTS: Of 1140 patients randomized, 742 had BRCA wild type (BRCAwt) tumors (HRP, n = 373; HRD/BRCAwt, n = 329). PFS hazard ratios between veliparib-throughout versus control were similar in both BRCAwt populations (HRD/BRCAwt: 22.9 vs 19.8 months; hazard ratio 0.76; 95% confidence interval [CI] 0.53-1.09; HRP: 15.0 vs 11.5 months; hazard ratio 0.765; 95% CI 0.56-1.04). By Cycle 3, the proportion with ≥90% CA-125 reduction from baseline was higher in those receiving veliparib (pooled arms) versus control (34% vs 23%; P = 0.0004); particularly in BRCAwt and HRP subgroups. Complete response rates among patients with measurable disease after surgery were 24% with veliparib (pooled arms) and 18% with control. CONCLUSIONS: These results potentially broaden opportunities for PARPi utilization among patients who would not qualify for frontline PARPi maintenance based on other trials.

Compound(41575-94-4)Name: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150》. Authors are Hopkins, Ashley M.; Kichenadasse, Ganessan; McKinnon, Ross A.; Abuhelwa, Ahmad Y.; Logan, Jessica M.; Badaoui, Sarah; Karapetis, Christos S.; Rowland, Andrew; Sorich, Michael J..The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).COA of Formula: C6H12N2O4Pt. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

Abstract: Background: Proton pump inhibitors (PPIs) are commonly used concomitant to cancer treatment and they induce gut microbiota changes. It is increasingly apparent that gut dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). However, little is known about PPI effects on outcomes with ICIs, particularly in combination, ICI approaches. Methods: Post hoc, Cox proportional hazard anal. of phase III trial, IMpower150 was conducted to assess the association between PPI use and overall survival (OS) and progression-free survival (PFS) in chemotherapy-naive, metastatic non-squamous non-small cell lung cancer participants randomised atezolizumab plus carboplatin plus paclitaxel (ACP), bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP (ABCP). PPI use was defined as any PPI administration between 30 days prior and 30 days after treatment initiation. Results: Of 1202 participants, 441 (37%) received a PPI. PPI use was independently associated with worse OS (n = 748; hazard ratio (HR) [95% confidence interval (CI)] = 1.53 [1.21-1.95], P < 0.001) and PFS (1.34 [1.12-1.61], P = 0.002) in the pooled atezolizumab arms (ACP plus ABCP). This association was not apparent for BCP (n = 368; OS 1.01 [0.73-1.39], P = 0.969; PFS 0.97 [0.76-1.25], P = 0.827). The observed OS treatment effect (HR 95% CI) of the atezolizumab (ACP plus ABCP) arms vs BCP was 1.03 (0.77-1.36) for PPI users compared to 0.68 (0.54-0.86) for non-users (P [interaction] = 0.028). A similar association was noted for ABCP vs BCP (PPI users 0.96 [0.68-1.35]; PPI non-users 0.66 [0.50-0.87]; P [interaction] = 0.095). Conclusions: PPI use was a neg. prognostic marker in patients treated with ACP or ABCP, but not BCP. The anal. suggests that PPIs neg. influence the magnitude of ICI efficacy. Compound(41575-94-4)COA of Formula: C6H12N2O4Pt received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Quality Control of (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine. Aromatic compounds can be divided into two categories: single heterocycles and fused heterocycles. Compound: (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine, is researched, Molecular C36H30NO2P, CAS is 415918-91-1, about Asymmetric synthesis of quaternary α-trifluoromethyl α-amino acids by Ir-catalyzed allylation followed by kinetic resolution. Author is Sun, Xi-Shang; Qiu, Ou-Yang; Xu, Shi-Ming; Wang, Xing-Heng; Tao, Hai-Yan; Chung, Lung Wa; Wang, Chun-Jiang.

Facile access to quaternary α-trifluoromethyl α-amino acids has been developed. This sequential reaction involves an Ir-catalyzed asym. allylation of α-trifluoromethyl aldimine esters followed by an unprecedented kinetic resolution

Compound(415918-91-1)Quality Control of (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (((4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(diphenylphosphine)(SMILESS: CC1(C)O[C@@H](CP(C2=CC=CC=C2)C3=CC=CC=C3)[C@H](CP(C4=CC=CC=C4)C5=CC=CC=C5)O1,cas:32305-98-9) is researched.Name: Pyridine-4-thiol. The article 《Selective and Scalable Synthesis of Sugar Alcohols by Homogeneous Asymmetric Hydrogenation of Unprotected Ketoses》 in relation to this compound, is published in Angewandte Chemie, International Edition. Let’s take a look at the latest research on this compound (cas:32305-98-9).

Sugar alcs. are of great importance for the food industry and are promising building blocks for bio-based polymers. Industrially, they are produced by heterogeneous hydrogenation of sugars with H2, usually with none to low stereoselectivities. Now, we present a homogeneous system based on com. available components, which not only increases the overall yield, but also allows a wide range of unprotected ketoses to be diastereoselectively hydrogenated. Furthermore, the system is reliable on a multi-gram scale allowing sugar alcs. to be isolated in large quantities at high atom economy.

Compound(32305-98-9)Recommanded Product: (((4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(diphenylphosphine) received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((((4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(diphenylphosphine)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 323196-43-6, is researched, Molecular C13H19ClN2O, about Medium-Ring Effects on the Endo/Exo Selectivity of the Organocatalytic Intramolecular Diels-Alder Reaction, the main research direction is ether fused cyclohexenecarboxaldehyde diastereoselective preparation; diastereoselectivity intramol Diels Alder reaction medium ring bridged trienal; imidazolidinone catalyst diastereoselectivity intramol Diels Alder reaction; transition state structure calculation intramol Diels Alder reaction; dependence diastereoselectivity intramol Diels Alder reaction size bridging ring; bromoperhydroisobenzofurancarboxylic acid oxatricyclotridecadienecarboxaldehyde nitrophenylhydrazone mol crystal structure; oxatricyclotetradecadienemethanol dinitrobenzoate mol crystal structure.HPLC of Formula: 323196-43-6.

Previous work showed that the butadienyloxoninylpropenal I (R = PhSiMe2) underwent diastereoselective intramol. Diels-Alder reactions in the presence of II•HCl or ent-II•HCl to yield either the endo cycloadduct III as the major cycloadduct in 15:1 dr (using ent-II) or the exo cycloadduct IV (suitable for elaboration to the eunicellins) as the sole diastereomer (using II). The diastereoselectivities of the intramol. Diels-Alder reactions of medium ring cyclic ether-containing trienecarboxaldehydes in the presence of II•HCl or ent-II•HCl and the calculated structures and enthalpies and free energies for diastereomeric transition state structures for the cycloadditions were determined The structures of a dibromoperhydroisobenzofurancarboxylic acid, an oxatricyclotridecadienecarboxaldehyde hydrazone, and an oxatricyclotetradecadienemethanol dinitrobenzoate were determined by X-ray crystallog.

Compound(323196-43-6)HPLC of Formula: 323196-43-6 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((R)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one hydrochloride), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(SMILESS: C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7,cas:415918-91-1) is researched.SDS of cas: 329-89-5. The article 《Ir/Zn Dual Catalysis: Enantioselective and Diastereodivergent α-Allylation of Unprotected α-Hydroxy Indanones》 in relation to this compound, is published in Organic Letters. Let’s take a look at the latest research on this compound (cas:415918-91-1).

A one-step enantioselective and diastereodivergent α-allylation of unprotected α-hydroxy indanones was developed using an Ir/Zn dual catalyst system; no addnl. base is required. The cyclic tertiary α-hydroxyketones containing vicinal stereocenters can be synthesized with excellent enantioselectivity (up to >99% ee) and good diastereoselectivity (up to 12:1 dr). By a simple choice of the appropriate chiral metal catalyst combination, all four product stereoisomers could be obtained from the same starting materials and under identical conditions.

Compound(415918-91-1)Synthetic Route of C36H30NO2P received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

SDS of cas: 32305-98-9. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: (((4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(diphenylphosphine), is researched, Molecular C31H32O2P2, CAS is 32305-98-9, about Palladium-catalyzed asymmetric formal [3+2] cycloaddition of α-N-heterocyclic acrylates with vinyl epoxides for construction of isonucleoside analogs. Author is Huang, Ke-Xin; Xie, Ming-Sheng; Wang, Dong-Chao; Sang, Ji-Wei; Qu, Gui-Rong; Guo, Hai-Ming.

A highly efficient Pd-catalyzed asym. formal [3+2] cycloaddition using α-N-heterocyclic acrylates to react with vinyl epoxides has been achieved for the first time to access chiral functionalized THF skeletons (34 examples, up to 93% yield, >20 : 1 dr and 99% ee). Meanwhile, using a palladium/(S,S)-tBu-FOXAP catalyst or a palladium/(R)-Segphos catalyst, purine or pyrimidine isonucleoside analogs are constructed in high yields and stereoselectivity, resp. The com. availability of the catalysts, broad substrate scope and easy transformation of the products make this methodol. an attractive method in asym. synthesis.

Compound(32305-98-9)SDS of cas: 32305-98-9 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound((((4R,5R)-2,2-Dimethyl-1,3-dioxolane-4,5-diyl)bis(methylene))bis(diphenylphosphine)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study.》. Authors are Moore, Kathleen N; Chambers, Setsuko K; Hamilton, Erika P; Chen, Lee-May; Oza, Amit M; Ghamande, Sharad A; Konecny, Gottfried E; Plaxe, Steven C; Spitz, Daniel L; Geenen, Jill J J; Troso-Sandoval, Tiffany A; Cragun, Janiel M; Rodrigo Imedio, Esteban; Kumar, Sanjeev; Mugundu, Ganesh M; Lai, Zhongwu; Chmielecki, Juliann; Jones, Suzanne F; Spigel, David R; Cadoo, Karen A.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).SDS of cas: 41575-94-4. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

PURPOSE: This study assessed the efficacy, safety, and pharmacokinetics of adavosertib in combination with four chemotherapy agents commonly used in patients with primary platinum-resistant ovarian cancer. PATIENTS AND METHODS: Women with histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled between January 2015 and January 2018 in this open-label, four-arm, multicenter, phase II study. Patients received adavosertib (oral capsules, 2 days on/5 days off or 3 days on/4 days off) in six cohorts from 175 mg once daily to 225 mg twice daily combined with gemcitabine, paclitaxel, carboplatin, or pegylated liposomal doxorubicin. The primary outcome measurement was overall response rate. RESULTS: Three percent of patients (3/94) had confirmed complete response and 29% (27/94) had confirmed partial response. The response rate was highest with carboplatin plus weekly adavosertib, at 66.7%, with 100% disease control rate, and median progression-free survival of 12.0 months. The longest median duration of response was in the paclitaxel cohort (12.0 months). The most common grade ≥3 adverse events across all cohorts were neutropenia [45/94 (47.9%) patients], anemia [31/94 (33.0%)], thrombocytopenia [30/94 (31.9%)], and diarrhea and vomiting [10/94 (10.6%) each]. CONCLUSIONS: Adavosertib showed preliminary efficacy when combined with chemotherapy. The most promising treatment combination was adavosertib 225 mg twice daily on days 1-3, 8-10, and 15-17 plus carboplatin every 21 days. However, hematologic toxicity was more frequent than would be expected for carboplatin monotherapy, and the combination requires further study to optimize the dose, schedule, and supportive medications.

Compound(41575-94-4)SDS of cas: 41575-94-4 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: (R)-5-Benzyl-2,2,3-trimethylimidazolidin-4-one hydrochloride, is researched, Molecular C13H19ClN2O, CAS is 323196-43-6, about Thiourea-catalyzed Diels-Alder reaction of a naphthoquinone monoketal dienophile.SDS of cas: 323196-43-6.

A variety of organocatalysts were screened for the catalysis of the naphthoquinone monoketal Diels-Alder reaction. Schreiner’s thiourea catalyst 10 and Jacobson’s thiourea catalyst 12 facilitate the cycloaddition of the sterically hindered naphthoquinone monoketal dienophile with diene. The use of thiourea catalysis allowed for the first time the highly selective synthesis of the exo-product Ethyl4-((tert-butyldimethylsilyl)oxy)-5,8-dimethoxy-2-methyl-10-oxo-4,4a,9a,10-tetrahydro-l/7-spiro[anthracene- 9,2′-[1,3]dioxolane]-9a-carboxylate in up to 63% yield. In this reaction a new quaternary center was built. The so formed cycloaddition product Ethyl4-((tert-butyldimethylsilyl)oxy)-5,8-dimethoxy-2-methyl-10-oxo-4,4a,9a,10-tetrahydro-l/7-spiro[anthracene- 9,2′-[1,3]dioxolane]-9a-carboxylate represents the ABC tricycle of beticolin 0(1) and is also a valuable model substrate for the total synthesis of related natural products.

In some applications, this compound(323196-43-6)SDS of cas: 323196-43-6 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine(SMILESS: C[C@@H](N(P1OC2=CC=C3C=CC=CC3=C2C4=C5C=CC=CC5=CC=C4O1)[C@@H](C6=CC=CC=C6)C)C7=CC=CC=C7,cas:415918-91-1) is researched.Synthetic Route of C17H19N3O2S. The article 《Stereodivergent Synthesis of Enantioenriched γ-Butyrolactones Bearing Two Vicinal Stereocenters Enabled by Synergistic Copper and Iridium Catalysis》 in relation to this compound, is published in Angewandte Chemie, International Edition. Let’s take a look at the latest research on this compound (cas:415918-91-1).

By virtue of a fundamentally new reaction model of azomethine ylide serving as a two-atom synthon, the first example of stereodivergent preparation of [(3R,4S)/(3S,4R)/(3R,4R)/(3S,4S)]-γ-butyrolactones I (R = Me, benzyl, allyl, 2-ethoxycarbonylethyl, etc.) via synergistic Cu/Ir-catalyzed asym. cascade allylation/lactonization is presented, and all four stereoisomers of I bearing two vicinal stereocenters are accessible with excellent diastereoselective and enantioselective control. The chiral IrIII- π-allyl intermediate was separated and characterized to understand the origin of the regio- and stereoselectivity of the initial C-C bond formation process. Control experiments shed some light on the catalyst/substrate and catalyst/catalyst interactions in this dual catalytic system to rationalize the related kinetic/dynamic kinetic resolution process with different catalyst combinations. The enantioenriched γ-butyrolactone products I were converted into an array of structurally complex chiral mols. and organocatalysts that were otherwise inaccessible.

In some applications, this compound(415918-91-1)Application In Synthesis of (11bR)-N,N-Bis[(1R)-1-phenylethyl]dinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepin-4-amine is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics